MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, has received a suspension order for one of its drug licenses in Andhra Pradesh.

Regulatory Action Details

The suspension order was issued by the Assistant Director, District Sales Licensing Authority, Drugs Control Administration, Vijayawada, Andhra Pradesh. The order specifically targets a store situated at Gollapudi One Center in Andhra Pradesh and was received on December 31, 2025.

Financial Impact

The company has quantified the potential financial impact of this regulatory action. The seven-day suspension is expected to result in a potential revenue loss of approximately ₹2.10 lakhs for the affected store operations.

Regulatory Compliance

The disclosure was made under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company followed SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, for this disclosure.

The violation falls under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945, though specific details of the contravention were not elaborated in the regulatory filing. The disclosure ensures transparency regarding regulatory actions that may impact the company's subsidiary operations and financial performance.

Medplus Health Services has announced that one of its subsidiaries is experiencing a drug license suspension in the state of Andhra Pradesh. The healthcare retail chain has disclosed this regulatory development along with its assessment of the potential financial implications.

Financial Impact Assessment

The company has projected the revenue loss from this license suspension at ₹2.10 lakhs. This represents the estimated financial impact on the subsidiary's operations due to the regulatory action.

Regulatory Compliance Matter

The drug license suspension affects the subsidiary's ability to operate in Andhra Pradesh, a key market for pharmaceutical retail operations. Such regulatory actions typically require companies to address compliance issues before normal operations can resume.

The relatively modest projected revenue loss suggests that the affected subsidiary may represent a smaller portion of the company's overall operations in the region, or that the suspension may be expected to be resolved within a limited timeframe.